A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Children's Cancer Group
• Treatments: Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Liposomal doxorubicin; Mitogens; Prednisone; Procarbazine; Vinblastine; Vincristine

Criteria

• Age less than 21 years at diagnosis

• Previously untreated, pathologically confirmed diagnosis of Hodgkin's disease.

• Informed patient/parental consent as required by individual institution and in accordance with the Dept of Health and Human Services

• Approval of this protocol by the individual institutional Human Subjects Review Committee.

• Indicate Hodgkin's disease clinical stage.

• Indicate presence or absence of "B" symptoms.

• For Stage I and II disease indicate the following:

• presence or absence of bulk disease

• number of involved nodal regions

• presence or absence of hilar adenopathy